Alamar Biosciences Launches NULISAseq Immune 340 Panel, Broadest Multiplexed Immune Profiling Solution Available For Translational Research And Drug Development
Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced the launch of the NULISAseq™ Immune 340 Panel, its broadest multiplexed
Alamar Biosciences released a new tool that can test many immune-system markers at once, which helps scientists and drug companies study diseases faster. This shows the company is growing its products, but it's too early to know if it will help the business make more money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.